about
Determination of sulfonamides in milk after precolumn derivatisation by micellar liquid chromatographySolvent properties of the 1-butyl-3-methylimidazolium hexafluorophosphate ionic liquidIonic matrices for matrix-assisted laser desorption/ionization time-of-flight detection of DNA oligomers.Therapeutic monitoring of imipramine and desipramine by micellar liquid chromatography with direct injection and electrochemical detection.Determination of liquid-liquid partition coefficients by separation methods.Retention mechanisms in micellar liquid chromatography.Countercurrent chromatography: people and applications.Validation of rapid microbiological methods.On the use of ionic liquids as mobile phase additives in high-performance liquid chromatography. A review.Micellar liquid chromatography in doping control.Performance of short-chain alcohols versus acetonitrile in the surfactant-mediated reversed-phase liquid chromatographic separation of β-blockers.Peak half-width plots to study the effect of organic solvents on the peak performance of basic drugs in micellar liquid chromatography.Quantitative structure-retention and retention-activity relationships of beta-blocking agents by micellar liquid chromatography.Half-width plots, a simple tool to predict peak shape, reveal column kinetics and characterise chromatographic columns in liquid chromatography: state of the art and new results.pH dependence of the hydrophobicity of beta-blocker amine compounds measured by counter-current chromatography.Elution-extrusion countercurrent chromatography. Use of the liquid nature of the stationary phase to extend the hydrophobicity window.Micellar versus hydro-organic mobile phases for retention-hydrophobicity relationship studies with ionizable diuretics and an anionic surfactant.Micellar liquid chromatography determination of some biogenic amines with electrochemical detection.Validation of micellar LC-based methods applied to analyze foodstuffs.Retention mechanisms for basic drugs in the submicellar and micellar reversed-phase liquid chromatographic modes.Development and validation of a method to determine amoxicillin in physiological fluids using micellar liquid chromatography.Amitriptyline and nortriptyline serum determination by micellar liquid chromatography.Ionic liquids versus triethylamine as mobile phase additives in the analysis of beta-blockers.Use of micellar liquid chromatography to analyze oxolinic acid, flumequine, marbofloxacin and enrofloxacin in honey and validation according to the 2002/657/EC decision.Determination of paroxetine in blood and urine using micellar liquid chromatography with electrochemical detection.Analysis of thiabendazole, 4-tert-octylphenol and chlorpyrifos in waste and sewage water by direct injection – micellar liquid chromatography.Are analysts doing method validation in liquid chromatography?Performance of different C18 columns in reversed-phase liquid chromatography with hydro-organic and micellar-organic mobile phasesFurosemide assay in pharmaceuticals by Micellar liquid chromatography: study of the stability of the drugUse of a three-factor interpretive optimisation strategy in the development of an isocratic chromatographic procedure for the screening of diuretics in urine samples using micellar mobile phasesSolvent systems for countercurrent chromatography: An aqueous two phase liquid system based on a room temperature ionic liquidSimultaneous determination of tyramine and tryptamine and their precursor amino acids by micellar liquid chromatography and pulsed amperometric detection in winesDetermination of trazodone in urine and pharmaceuticals using micellar liquid chromatography with fluorescence detectionUse of micellar mobile phases for the chromatographic determination of melamine in dietetic supplementsQuinolones control in milk and eggs samples by liquid chromatography using a surfactant-mediated mobile phaseIs it really necessary to validate an analytical method or not? That is the questionDirect determination of verapamil in urine and serum samples by micellar liquid chromatography and fluorescence detectionMicellar liquid chromatographic determination of five antianginals in pharmaceuticalsHydrophobicity of ionisable compounds studied by countercurrent chromatographyMonitoring of HAART regime antiretrovirals in serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography
P50
Q28049490-B54E3F26-FE03-48DE-91A8-62271A864ED2Q28206516-71C3E1F5-6B2A-4816-BB33-D36237E9F33AQ30891880-74C81F22-4FFF-4655-9D04-43BB609286FBQ31134868-065B3907-6F0F-49FE-941D-AF154D80C57FQ34328736-8E7D3258-9EBA-4F43-A236-552FDC68FDA4Q37288054-6C2CFBCC-D8C5-4CAB-9B46-4E3E68B34504Q37318345-7643F0A6-6392-4B16-B31A-9CECDA200BEEQ38259073-CC979BDB-2033-4DE6-8296-42027150A2D8Q38531646-5E49D279-A38F-4E31-8F5A-8EC578469FD6Q42807371-96DF1689-644A-41A5-B556-D413948073E1Q42863839-96A83CBF-1D2D-4C48-A10A-F371BD4BA7B0Q43173068-9A2B07E5-1890-45FA-8DB5-5899D23A1549Q43593563-99361BF7-7E27-4A2B-9AC2-69279BF80F2AQ44288676-9D48C122-CACE-4A8D-8340-E098353E1C22Q44474310-4AE5C62E-7446-4A43-865F-FA1620DBDD8CQ44638318-4A183E29-4C3E-42DE-A52A-C1E1577B6F21Q44813717-B02A9A13-CD82-49FA-9BD8-9A6D912AEC9FQ45116813-49A81714-37AB-4CA7-AC6B-99377D16953AQ46067782-E4642249-89BD-494A-BBBE-2EBC33AE7588Q46203872-C5DEB3A9-BF28-4D06-9C48-5E8901E8847EQ46455826-F49167A1-AC1F-46FE-BA14-BFC360F21A1BQ46620500-CB9AF574-8C79-4113-9F16-C3CAF9ABE94EQ46873589-7CAE01D3-AE70-4CB4-8600-1DD6FB8222F3Q47882248-EB60AC4A-1A06-47EB-9539-85F7F0DF78BFQ48366799-C844E08A-7722-4597-84D6-423DC95EEB10Q52789196-C260DDCE-D0E6-4125-92CF-14365678F6BEQ60640531-0BC64315-DC7D-4A33-A54A-AA6D6A0BF03CQ60640537-6CA5E241-26DA-46F3-8361-64B2833A7C0CQ60640710-50B2E6F1-C383-49EC-B04F-F1DB25C78BD6Q60640719-20ED3971-B6D8-47BA-993B-AC726839143FQ61823536-FE44E14C-AB46-456E-BB1B-D59D17C4E5AAQ80072759-030E17B4-5F1B-4B35-BE0C-6C04409672C0Q80199642-0EC4EB43-AE9A-42EB-A4B9-A92DA990BA5FQ82415580-3ABCF3E9-314D-4808-AAFF-7D0EA8CE71DAQ82495374-13556FFF-C8ED-4D71-8F24-A53EEE69FEABQ82588314-DFD85F59-0BE7-434D-ABE7-B7432B47A9AAQ83169433-F8E5EF77-0F56-4503-9686-62DB4D144E1EQ83219517-4145A1A9-2A4D-4375-813A-48EE44A35A97Q83304288-77C9992A-E128-48EB-8F0D-C9A43660101EQ84713955-DC2136EF-B652-4D12-AEAD-8B760F3A1029
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Samuel Carda-Broch
@ast
Samuel Carda-Broch
@en
Samuel Carda-Broch
@es
Samuel Carda-Broch
@nl
type
label
Samuel Carda-Broch
@ast
Samuel Carda-Broch
@en
Samuel Carda-Broch
@es
Samuel Carda-Broch
@nl
prefLabel
Samuel Carda-Broch
@ast
Samuel Carda-Broch
@en
Samuel Carda-Broch
@es
Samuel Carda-Broch
@nl
P106
P1153
6603722860
P21
P31
P496
0000-0002-4859-0308